An interventional study of Electronic Health Record Review and Liver Biopsy in Portal Hypertension, sponsored by Mayo Clinic. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Hypertension, Portal with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Hypertension, Portal · United States.
Among the 59 studies in Hypertension, Portal with a site in United States, this one is the 18th largest by planned enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2025, is one of 20 with no phase, and was the 54th registered.
376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.
Browse Hypertension, Portal studies →7 of the 59 studies in Hypertension, Portal with a site in United States are open now. Recruiting first, the newest first:
W.L.Gore & Associates · Sites in United States, Italy
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–99
Thomas Jefferson University · Sites in United States, Switzerland
Ages 18+
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 12–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Hypertension, Portal studies recruiting now, 33 (49%) set no upper age limit and 12 (18%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 15 · Phase 3 12 · Phase 4 3
First in 1993; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 232 interventional studies indexed under Hypertension, Portal.
Median enrollment 30 across the 47 interventional studies, 70 across the 12 observational. Of the 45 that completed or were terminated, 23 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 3 studies filed under Hypertension, Portal — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypertension, Portal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07046429Weill Medical College of Cornell UniversityAffect of Melatonin on Sleep and Cognition in Cirrhosis | 2026-12-31 |
| NCT06797193Mayo ClinicUltrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies in Hypertension, Portal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial tests the how well an ultrasound with subharmonic imaging and the subharmonic aided pressure estimation (SHAPE) technique works in identifying portal hypertension (PH). An ultrasound takes pictures of the inside of the body by bouncing sound waves off organs. PH is high blood pressure in the vein that carries blood to the liver from the stomach, small and large intestines, spleen, pancreas, and gallbladder. The complications associated with PH are clear only after severe liver dysfunction or liver cirrhosis develops and are accompanied by relatively high mortality rates (20-70% mortality within 2 years). Thus, identifying PH earlier is beneficial. The hepatic venous pressure gradient (HVPG) obtained using an invasive catheterization procedure remains the standard for assessing PH. However, using this invasive procedure to assess PH prevents frequent pressure monitoring. Thus, a noninvasive technique to estimate PH is beneficial not only for diagnosis but also for monitoring treatment and disease progression. The SHAPE technique is a noninvasive ultrasound-based imaging technique that can estimate pressure with an ultrasound contrast agent. A noninvasive technique using an ultrasound with subharmonic imaging and the SHAPE technique may work in identifying PH.
PRIMARY OBJECTIVES:
I. To evaluate if SHAPE with perflutren lipid microspheres (Definity) microbubbles identifies patients with clinically significant PH.
II. To evaluate if addition of subharmonic imaging-based perfusion parameters derived from time intensity curves and shear wave elastography (SWE) measurements increase the diagnostic confidence of detecting PH.
OUTLINE:
Patients receive Definity intravenously (IV) once on study. Additionally, patients undergo ultrasound with and without SHAPE technique as well as standard of care liver biopsy on study.
After completion of study intervention, patients are followed up for 30 minutes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive Definity IV once on study. Additionally, patients undergo ultrasound with and without SHAPE technique as well as standard of care liver biopsy on study.
Other: Electronic Health Record Review · Procedure: Liver Biopsy · Other: Medical Device Usage and Evaluation · Drug: Perflutren Lipid Microspheres · Procedure: Ultrasound Imaging
Ancillary studies
Undergo liver biopsy
Also known as: Biopsy of Liver
Undergo ultrasound with SHAPE technique
Given IV
Also known as: Definity
Undergo ultrasound
Also known as: 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
Clinically significant portal hypertension (PH)
Will evaluate if subharmonic aided pressure estimation with Definity microbubbles identifies patients with clinically significant PH.
Time frame: Baseline (at time of ultrasound)
Diagnostic confidence
Will evaluate if the addition of subharmonic imaging-based perfusion parameters increase the diagnostic confidence of detecting PH.
Time frame: Baseline (at time of ultrasound)
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.
Of 57 non-industry interventional studies with no phase under Hypertension, Portal, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 72. This study's planned 24 months is below that.
Counting every sponsor, half of 61 studies reached it within 41 months; a quarter within 19 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Perflutren